Stay updated on Asciminib Combo with Imatinib in CML-CP Clinical Trial
Sign up to get notified when there's something new on the Asciminib Combo with Imatinib in CML-CP Clinical Trial page.

Latest updates to the Asciminib Combo with Imatinib in CML-CP Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedTaoyuan District, Taiwan, 33305 was replaced with Taoyuan, Taiwan, 33305 in the Locations section. This updates the listed site to reflect the correct municipality.SummaryDifference0.0%

- Check20 days agoChange DetectedThe study record has been updated to reflect an additional **asciminib 80 mg single-agent cohort (ASAC)** added after the primary analysis, alongside the ongoing randomized add-on/switch/continue arms. Corresponding **primary/secondary outcome measure definitions** and related endpoint timing (e.g., **MR4.5 rates at 48 and 96 weeks** and related analyses) were also updated to include this single-agent evaluation.SummaryDifference4%

- Check27 days agoChange DetectedRevision added: v3.5.2. Revision removed: v3.5.0.SummaryDifference0.0%

- Check56 days agoChange DetectedPage revision tag updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check70 days agoChange DetectedRevision: v3.4.3 added and Revision: v3.4.2 removed.SummaryDifference0.0%

- Check91 days agoChange DetectedRevision: v3.4.2 was added and Revision: v3.4.1 was removed, indicating a system update. No core study content, locations, or outcomes appear to be altered. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to Asciminib Combo with Imatinib in CML-CP Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Asciminib Combo with Imatinib in CML-CP Clinical Trial page.